PriceTargets.com logo

Abivax - ABVX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $128.73
  • Forecasted Upside: 13.31%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$113.61 As of 12/18/2025 05:00 PM ET
▲ +2.79 (2.52%)

This chart shows the closing price for ABVX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Abivax Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABVX

Analyst Price Target is $128.73
▲ +13.31% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Abivax in the last 3 months. The average price target is $128.73, with a high forecast of $176.00 and a low forecast of $74.00. The average price target represents a 13.31% upside from the last price of $113.61.

This chart shows the closing price for ABVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 investment analysts is to moderate buy stock in Abivax. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 2 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/18/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2025GuggenheimReiterated RatingBuy ➝ Buy$175.00
12/16/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$142.00
12/16/2025CitigroupReiterated RatingOutperform ➝ Outperform
12/16/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$114.00 ➝ $131.00
11/24/2025Truist FinancialSet Target$140.00
11/24/2025Truist FinancialInitiated CoverageBuy$140.00
11/6/2025Wolfe ResearchUpgradeStrong-Buy
11/5/2025Wolfe ResearchInitiated CoverageOutperform$176.00
11/4/2025CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
10/13/2025BarclaysInitiated CoverageOverweight$142.00
10/13/2025BarclaysInitiated CoverageOverweight$142.00
10/10/2025GuggenheimBoost TargetBuy ➝ Buy$101.00 ➝ $150.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/6/2025BTIG ResearchBoost TargetBuy ➝ Buy$112.00 ➝ $120.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/25/2025CitigroupReiterated RatingOutperform ➝ Outperform
9/25/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$95.00 ➝ $114.00
9/12/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$71.00 ➝ $101.00
9/9/2025BTIG ResearchReiterated RatingBuy ➝ Buy$112.00
7/29/2025Piper SandlerBoost TargetOverweight ➝ Overweight$70.00 ➝ $112.00
7/23/2025Leerink PartnersSet TargetOutperform ➝ Outperform$74.00
7/23/2025Lifesci CapitalBoost TargetOutperform ➝ Outperform$45.00 ➝ $101.00
7/23/2025Piper SandlerBoost TargetOverweight ➝ Overweight$42.00 ➝ $70.00
7/23/2025GuggenheimBoost TargetBuy ➝ Buy$50.00 ➝ $101.00
7/23/2025Morgan StanleyUpgradeEqual Weight ➝ Overweight$71.00
7/23/2025JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $95.00
7/18/2025JMP SecuritiesSet Target$33.00
7/18/2025CitigroupReiterated RatingMarket Outperform ➝ Market Outperform
4/30/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.00
3/20/2025Morgan StanleyReiterated RatingEqual Weight$12.00
1/10/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.00
12/4/2024Citizens JmpUpgradeStrong-Buy
12/4/2024JMP SecuritiesInitiated CoverageOutperform$33.00
7/29/2024LaidlawInitiated CoverageBuy$48.00
5/20/2024BTIG ResearchInitiated CoverageBuy$43.00
4/29/2024Piper SandlerInitiated CoverageOverweight$42.00
4/29/2024GuggenheimInitiated CoverageBuy$50.00
4/11/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$15.00 ➝ $16.00
11/14/2023Leerink PartnrsReiterated RatingOutperform
11/14/2023Morgan StanleyInitiated CoverageEqual Weight$15.00
11/14/2023Leerink PartnersInitiated CoverageOutperform$20.00
(Data available from 12/18/2020 forward)

News Sentiment Rating

0.53 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2025
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2025
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2025
  • 9 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2025
  • 16 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2025
  • 9 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2025
  • 3 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2025
  • 13 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2025

Current Sentiment

  • 13 very positive mentions
  • 28 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Abivax logo
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Read More

Today's Range

Now: $113.61
Low: $112.01
High: $117.72

50 Day Range

MA: $108.31
Low: $90.47
High: $133.09

52 Week Range

Now: $113.61
Low: $4.77
High: $138.49

Volume

919,718 shs

Average Volume

1,776,467 shs

Market Capitalization

$8.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Abivax?

The following sell-side analysts have issued stock ratings on Abivax in the last year: Barclays PLC, BTIG Research, Citigroup Inc., Citizens Jmp, Guggenheim, JMP Securities, Leerink Partners, Lifesci Capital, Morgan Stanley, Piper Sandler, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, and Wolfe Research.
View the latest analyst ratings for ABVX.

What is the current price target for Abivax?

0 Wall Street analysts have set twelve-month price targets for Abivax in the last year. Their average twelve-month price target is $128.73, suggesting a possible upside of 13.3%. Wolfe Research has the highest price target set, predicting ABVX will reach $176.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $74.00 for Abivax in the next year.
View the latest price targets for ABVX.

What is the current consensus analyst rating for Abivax?

Abivax currently has 1 sell rating, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ABVX.

What other companies compete with Abivax?

Other companies that are similar to Abivax include BeOne Medicines, Teva Pharmaceutical Industries, BioNTech, Genmab A/S and Roivant Sciences. Learn More about companies similar to Abivax.

How do I contact Abivax's investor relations team?

The company's listed phone number is 33-1-53-83-09-63 and its investor relations email address is [email protected]. The official website for Abivax is www.abivax.com. Learn More about contacing Abivax investor relations.